P
Pernille Ravn
Researcher at Odense University Hospital
Publications - 196
Citations - 7491
Pernille Ravn is an academic researcher from Odense University Hospital. The author has contributed to research in topics: Osteoporosis & Bone density. The author has an hindex of 43, co-authored 179 publications receiving 6886 citations. Previous affiliations of Pernille Ravn include Gentofte Hospital & University of Copenhagen.
Papers
More filters
Journal ArticleDOI
Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.
David J. Hosking,C. E. D. Chilvers,C. Christiansen,Pernille Ravn,R. D. Wasnich,Philip D. Ross,Michael R. McClung,Ana Balske,D. E. Thompson,M. Daley,A. J. Yates +10 more
TL;DR: Estrogen-replacement therapy prevents osteoporosis in postmenopausal women by inhibiting bone resorption, but the balance between its long-term risks and benefits remains unclear.
Journal ArticleDOI
Low Body Mass Index Is an Important Risk Factor for Low Bone Mass and Increased Bone Loss in Early Postmenopausal Women
Pernille Ravn,Giovanni Cizza,Nina H. Bjarnason,Desmond E. Thompson,M. Daley,R. D. Wasnich,Michael R. McClung,David J. Hosking,A. J. Yates,C. Christiansen +9 more
TL;DR: Thinness is an important risk factor for low bone mass and increased bone loss in postmenopausal women and because the response to alendronate treatment is independent of fat mass parameters, prevention of post menopausal osteoporosis can be equally achieved in thinner and heavier women.
Journal ArticleDOI
Prevention of Bone Loss With Alendronate in Postmenopausal Women Under 60 Years of Age
David J. Hosking,C. E. D. Chilvers,C. Christiansen,Pernille Ravn,Richard D. Wasnich,Philip D. Ross,Michael R. McClung,Ana Balske,D. E. Thompson,M. Daley,A. J. Yates +10 more
TL;DR: Alendronate prevents bone loss in postmenopausal women under 60 years of age to nearly the same extent as estrogen-progestin and was well tolerated, with a safety profile similar to that of placebo or estrogen- Progestin.
Journal ArticleDOI
Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial
Michael R. McClung,B Clemmesen,Daifotis Anastasia G,N L Gilchrist,John A. Eisman,Robert S. Weinstein,Fuleihan G el-H,C Reda,A. J. Yates,Pernille Ravn +9 more
TL;DR: A 3-year randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy of alendronate therapy in preventing bone loss in healthy women who had recently experienced menopause.
Journal ArticleDOI
Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study
Yu Z. Bagger,László B. Tankó,Peter Alexandersen,Henrik Bo Hansen,Anette Møllgaard,Pernille Ravn,Per Qvist,John A. Kanis,Claus Christiansen +8 more
TL;DR: Limited HRT administered in the early postmenopausal years offers long-lasting benefits for the prevention of post menopausal bone loss and osteoporotic fracture.